2 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow Carcinoid Tumor: new trials by email Literature Review of Carcinoid Tumor trials Research Report on Carcinoid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients arginine/lysine - Gastroenteropancreatic Neuroendocrine Tumors | Phase 4 | Completed | Advanced Accelerator Applications | 42 | 2021-01-25 | 2025-01-24 |
| Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Everolimus, Sandostatin LAR Depot - Neoplasms | Phase 4 | Completed | Novartis Pharmaceuticals | 34 | 2013-05-14 | 2021-06-11 |
Neuroendocrine Tumors (2) · Gastro-enteropancreatic neuroendocrine tumor (1) · Neoplasms (1)
Adenocarcinoma (2) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neoplasms (1)
Everolimus (1) · Octreotide (1) · arginyllysine (1)
Advanced Accelerator Applications (1) · Novartis Pharmaceuticals (1)
Italy (2) · Netherlands (2) · Czechia (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Thailand (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)
2019 (1)